Diversified healthcare company CVS Health (NYSE:CVS) announced in Q1 CY2025, with sales up 7% year on year to $94.59 billion.

CVS reported first quarter earnings Thursday, blowing past Wall Street's expectations and ending anxiety over Medicare ...

Shares of CVS Health Corporation (CVS) traded 10% higher in pre-market on Thursday after the company reported better-than-expected first-quarter (Q1) earnings and raised its full-year profit guidance.

CVS Health (NYSE: CVS) raised its full-year 2025 adjusted EPS guidance to a range of $6.00 to $6.20, up from its previous forecast of $5.75 to $6.00 and above the analyst consensus of $5.91.

CVS Health sees strong Q1 2025 growth, but risks loom with downgraded revenue guidance and Medicare challenges. Read my analysis on CVS stock's earnings here.

CVS Health Corp posted a strong first quarter in 2025, with earnings per share (EPS) of $2.25, surpassing the forecast of $1.64. The company’s revenue reached nearly $95 billion, exceeding ...

CVS Health reported robust year-over-year growth in Q1 2025 earnings, with significant increases in sales, revenue, and net income, though the company adjusted its annual earnings guidance downward.

Full Year Cash Flow Guidance: Updated to approximately $7 billion. CVS Health Corp (NYSE:CVS) reported strong financial results for Q1 2025, with adjusted earnings per share of $2.25 and adjusted ...

Activist investor Glenview Capital is reducing its stake in healthcare giant CVS Health following its first-quarter earnings ...

CVS (CVS) reported first quarter earnings Thursday, beating Wall Street's expectations. The company also raised its full-year 2025 guidance, with adjusted earnings per share now expected in the ...

CVS Health Corp posted a strong first quarter in 2025, with earnings ... guidance to $6.00-$6.20. Stock price increased by 8.8% in premarket trading. Strategic partnerships and innovations are driving ...